Clonazepam and Relapsing-remitting multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Relapsing-remitting multiple sclerosis is reported as a side effect among people who take Clonazepam (clonazepam), especially for people who are female, 30-39 old, also take Vitamin D, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Relapsing-remitting multiple sclerosis when taking Clonazepam. It is created by eHealthMe based on reports of 140,365 people who have side effects when taking Clonazepam from the FDA, and is updated regularly.

What is Clonazepam?

Clonazepam has active ingredients of clonazepam. It is often used in stress and anxiety. eHealthMe is studying from 146,271 Clonazepam users. Check the latest studies of Clonazepam.

What is Relapsing-remitting multiple sclerosis?

Relapsing-remitting multiple sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 126 drugs and 178 conditions by eHealthMe. Check the latest studies of Relapsing-remitting multiple sclerosis.

On Aug, 04, 2026

140,365 people reported to have side effects when taking Clonazepam.
Among them, 23 people (0.02%) have Relapsing-remitting multiple sclerosis.

Could Clonazepam cause Relapsing-remitting multiple sclerosis?

Among these 23 people:

What is the gender of people who have Relapsing-remitting multiple sclerosis when taking Clonazepam? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Relapsing-remitting multiple sclerosis when taking Clonazepam? *

What are other drugs people take besides Clonazepam? *

What are other side effects people have besides Relapsing-remitting multiple sclerosis? *

Memory Loss: 6 people, 26.09%
Nausea (feeling of having an urge to vomit): 5 people, 21.74%
Gait Disturbance: 5 people, 21.74%
Pain In Extremity: 4 people, 17.39%
Dizziness: 4 people, 17.39%
Constipation: 4 people, 17.39%
Muscle Spasms (muscle contraction): 4 people, 17.39%
Mobility Decreased (ability to move is reduced): 3 people, 13.04%
Diarrhea: 3 people, 13.04%
Back Pain: 3 people, 13.04%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 9 people, 39.13%
Depression: 4 people, 17.39%
Insomnia (sleeplessness): 3 people, 13.04%
Gait Disturbance: 3 people, 13.04%
Sleep Disorder: 2 people, 8.70%
Diarrhea: 2 people, 8.70%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 8.70%
Tremor (trembling or shaking movements in one or more parts of your body): 2 people, 8.70%
Hot Flush (sudden feelings of heat): 1 person, 4.35%
Cataract (clouding of the lens inside the eye): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Clonazepam and have Relapsing-remitting multiple sclerosis?

- Check whether Relapsing-remitting multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Clonazepam:

Clonazepam (146,271 reports)

Relapsing-remitting multiple sclerosis treatments and more:

Relapsing-remitting multiple sclerosis (76,275 reports)

How severe was Relapsing-remitting multiple sclerosis and when was it recovered:

Relapsing-remitting multiple sclerosis in Clonazepam

Expand to all the drugs that have ingredients of clonazepam:

Relapsing-remitting multiple sclerosis and drugs with ingredients of clonazepam

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Clonazepam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Relapsing-remitting multiple sclerosis:

Relapsing-remitting multiple sclerosis (126 drugs)

Browse all the conditions that are associated with Relapsing-remitting multiple sclerosis:

Relapsing-remitting multiple sclerosis (178 conditions)

Related publications that referenced our studies

McFarlane SI, "Torsades de Pointes induced by Methadone and Clonazepam Use", , 2015 Jan .
Ashkar AG, Goldberg T, Maraj I, Masters A, McFarlane SI, "Torsades De Pointes Induced by Methadone and Clonazepam Use", International Journal of Medical and Pharmaceutical Case Reports, 2015 Jan .
McFarlane, S. I. , "Torsades de Pointes induced by Methadone and Clonazepam Use", , 2014 Jan .
McFarlane SI, "Torsades de Pointes induced by Methadone and Clonazepam Use", , 2015 Jan .
Ashkar AG, Goldberg T, Maraj I, Masters A, McFarlane SI, "Torsades De Pointes Induced by Methadone and Clonazepam Use", International Journal of Medical and Pharmaceutical Case Reports, 2015 Jan .
McFarlane, S. I. , "Torsades de Pointes induced by Methadone and Clonazepam Use", , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on clonazepam (the active ingredients of Clonazepam) and Clonazepam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.